



SurModics to Present at Canaccord Genuity Medical Technology & Diagnostics Conference

November 12, 2013

Webcast is Live on Thursday, November 14, at 1 p.m. (CT)

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Nov. 12, 2013-- SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industry, announced today that Andy LaFrence, vice president of finance and chief financial officer, will make a presentation to the investment community at the Canaccord Genuity Medical Technology & Diagnostics Conference on Thursday, November 14, 2013, at 1 p.m. CT (2 p.m. ET) in New York City.

A live audio webcast of the presentation will be available by going to the investor relations portion of the Company's website at www.surmodics.com and clicking on the webcast icon. At the end of the day on Thursday, November 14, the audio and slide presentation will be archived on the Company's website for 90 days.

About SurModics, Inc.

SurModics' mission is to exceed our customers' expectations and enhance the well-being of patients by providing the world's foremost, innovative surface modification technologies and *in vitro* diagnostic chemical components. The Company partners with the world's leading and emerging medical device, diagnostic and life science companies to develop and commercialize innovative products designed to improve patient diagnosis and treatment. Core offerings include surface modification coating technologies that impart lubricity, prohealing, and biocompatibility capabilities; and components for *in vitro* diagnostic test kits and microarrays. SurModics is headquartered in Eden Prairie, Minnesota. For more information about the Company, visit www.surmodics.com. The content of SurModics' website is not part of this press release or part of any filings that the Company makes with the SEC.

Source: SurModics, Inc.

SurModics, Inc.

Andy LaFrence, 952-500-7000

ir@surmodics.com